Premature Ovarian Insufficiency and Mesenchymal stem/stromal cells (MSC): what the trial registry contains

Why this is studied in Premature Ovarian Insufficiency

Primary ovarian insufficiency is loss of ovarian function before forty, from genetic, autoimmune or iatrogenic causes. Cell and platelet-based 'ovarian rejuvenation' aims to restore folliculogenesis. Occasional spontaneous ovulation occurs in this condition — including spontaneous pregnancies — which is the fact most often exploited by uncontrolled case reports.

What MSC means in this table

Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.

The numbers

Every figure below comes from one reproducible query (primary ovarian insufficiency x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Registration activity is thin and early: 18 records in total, none at confirmatory phase, 2 recruiting.

Registrations do not all survive contact with recruitment — 3 completed here, 2 stopped early, giving a 11% attrition rate.

Median planned enrolment is 34 participants (largest single study: 320). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

8 countries host at least one site. China is the largest single contributor at roughly 56% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Among the top lead sponsors, 3 are universities or hospitals and 5 are companies, making this a commercial area.

• Chinese Academy of Sciences — 3 records
• Ukraine Association of Biobank — 1 record
• Shenzhen Wingor Biotechnology Co., Ltd. — 1 record
• CHABiotech CO., Ltd — 1 record
• Bright Cell, Inc. — 1 record
• Vitti Labs, LLC — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many MSC studies for Premature Ovarian Insufficiency are recruiting right now?

2 of 18 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is MSC an approved treatment for Premature Ovarian Insufficiency?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 18 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on MSC for Premature Ovarian Insufficiency?

0 of 18 records carry a Phase 3 or Phase 4 label and 3 are marked completed. Registrations run from 2012 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.